For cohorts with emergent MCL-1 compensation in dynamic BH3 profiling, the cellular product can be upgraded to co-deliver NOXA (or granzyme B-NOXA fusions) or it can be combined with transient, tumor-confined MCL-1 antagonists while maintaining BCL-xL targeting. The gene discussed is BCL2L1; the disease is neoplasm.